← All indications
Hepatitis, Alcoholic
INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.
Drugs by status
Phase 4 trials (10)
Phase 3 trials (8)
Phase 2 trials (19)
Phase 1 trials (2)
Organizations
Organization Involved with Phase 4 Indications (6)
Organization Involved with Phase 3 Indications (15)
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- University of London
- Inje University
- University of Louisville
- University of Rochester
- Institute of Liver and Biliary Sciences, India
- University of Lille
- Dayanand Medical College
- Catholic University of Korea
- University of Massachusetts
- Erasmus University Rotterdam
- Government of France
- University of Picardie Jules Verne
- The University of Texas, Dallas
- Rajasthan University of Health Sciences
Organization Involved with Phase 2 Indications (30)
- Gilead Sciences
- Intercept Pharmaceuticals
- Novartis
- CTI BioPharma
- Immuron Ltd.
- PharmaKing
- Afimmune
- Durect
- National Institutes of Health (NIH)
- National Center for Complementary and Integrative Health (NCCIH)
- Southern California Institute for Research and Education
- Indiana University
- Loma Linda University
- Los Angeles Biomedical Research Institute
- University of Nottingham
- University of Southern California
- Virginia Commonwealth University
- Mayo Clinic
- University of California, Los Angeles
- Badalona Hospital Germans Trias i Pujol
- Conatus Pharmaceuticals
- Hennepin Healthcare
- Universidad Autonoma de Barcelona
- Hospital de Sant Pau i Santa Tecla de Tarragona
- Department of Veteran Affairs
- Office of Dietary Supplements (ODS)
- CTI Clinical Trial and Consulting Services
- Imperial College London
- IQVIA
- Akaza Bioscience Ltd
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (4)